Mark Mobius discusses investment strategies amidst geopolitical tensions and market dynamics. He highlights India’s potential, contingent on regulatory reforms, and identifies defense, IT, and pharmaceuticals as promising sectors. Mobius also notes Trump’s influence on markets and the US-China dynamic, emphasizing the need for vigilance regarding trade agreements.
5 pharma stks with upside potential of up to 12%
Nifty Pharma index has moved in tandem with the headline index, with nearly 5% returns in the last month, with stocks gaining by up to
June 12, 2025